The Italian Network for Tumor Biotherapy (NIBIT): Getting together to push the field forward

Journal of Translational Medicine

Volumn 6, Issue , 2008, Pages

  Maio, Michele ^a,b   Nicolay, Hugues J M ^a,b   Ascierto, Paolo ^c   Belardelli, Filippo ^d   Camerini, Roberto ^e   Colombo, Mario P ^f   Queirolo, Paola ^g   Ridolfi, Ruggero ^h   Russo, Vincenzo ⁱ   Anzalone, Lucia ^a   Fonsatti, Ester ^a   Parmiani, Giorgio ⁱ  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^e Sigma Tau SpA   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g UNIVERSITY OF GENOA   (Italy)

^h DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

ⁱ SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BOSENTAN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; DCVAX; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; GLYCOPROTEIN GP 100; IMMUNOMODULATING AGENT; INDOLEAMINE 2,3 DIOXYGENASE INHIBITOR; INTERLEUKIN 2; IPILUMUMAB; MELANOMA ANTIGEN 3; MONTANIDE ISA 51; NY ESO 1 ANTIGEN; OMI 1; PEGINTERFERON ALPHA2B; PEPTIDE VACCINE; PLACEBO; PLATINUM DERIVATIVE; SURVIVIN; THYMOSIN ALPHA1; TICILIMUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ADJUVANT THERAPY; ARTICLE; B LYMPHOCYTE ACTIVATION; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GENE THERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL LYSATE; CELL THERAPY; CELLULAR IMMUNITY; CLINICAL RESEARCH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPETITIVE INHIBITION; DENDRITIC CELL; DNA SEQUENCE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EFFECTOR CELL; EPIGENETICS; GENE EXPRESSION PROFILING; GLIOBLASTOMA; HUMAN; HUMORAL IMMUNITY; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; INFORMATION DISSEMINATION; ITALY; LUNG NON SMALL CELL CANCER; MALIGNANT MESOTHELIOMA; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; MEDICAL EDUCATION; MELANOMA; MOLECULAR MECHANICS; MONOTHERAPY; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PATIENT INFORMATION; REGULATORY T LYMPHOCYTE; SARCOMA; STEM CELL TRANSPLANTATION; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT; VACCINATION; ANIMAL; BIOLOGICAL THERAPY; CONFERENCE PAPER; COOPERATION; GENETIC EPIGENESIS; GENETICS; IMMUNOLOGY; MOUSE; NEOPLASM; TUMOR ESCAPE;

ANIMALS; BIOLOGICAL THERAPY; CANCER VACCINES; COOPERATIVE BEHAVIOR; EPIGENESIS, GENETIC; HUMANS; ITALY; MICE; NEOPLASMS; TUMOR ESCAPE; VACCINATION;

EID: 41549104201     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-6-8     Document Type: Article

References (38)

1. Webb C Pass H Translation research: From accurate diagnosis to appropriate treatment Journal of Translational Medicine 2004, 2:35. 524522 15496233 10.1186/1479-5876-2-35
2. Ioannidis J Materializing research promises: Opportunities, priorities and conflicts in translational medicine Journal of Translational Medicine 2004, 2:5. 343300 14754464 10.1186/1479-5876-2-5
3. Parks M Disis M Conflicts of interest in translational research Journal of Translational Medicine 2004, 2:28. 514574 15301694 10.1186/ 1479-5876-2-28
4. Lehmann F Lacombe D Therasse P Eggermont A Integration of Translational Research in the European Organization for Research and Treatment of Cancer Research (EORTC) Clinical Trial Cooperative Group Mechanisms Journal of Translational Medicine 2003, 1:2. 202358 14527343 10.1186/ 1479-5876-1-2
5. Marincola E Why is public science education important? Journal of Translational Medicine 2006, 4:7. 1395333 16433911 10.1186/1479-5876-4-7
6. Grohmann U Volpi C Fallarino F Bozza S Bianchi R Vacca C Orabona C Belladonna ML Ayroldi E Nocentini G Boon L Bistoni F Fioretti MC Romani L Riccardi C Puccetti P Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy Nat Med 2007, 13:579-586. 10.1038/nm1563 17417651
7. Sica A Bronte V Altered macrophage differentiation and immune dysfunction in tumor development J Clin Invest 2007, 117:1155-1166. 1857267 17476345 10.1172/JCI31422
8. Sigalotti L Fratta E Coral S Cortini E Covre A Nicolay HJ Anzalone L Pezzani L Di Giacomo AM Fonsatti E Colizzi F Altomonte M Calabro L Maio M Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol 2007, 212:330-344. 10.1002/jcp.21066 17458893
9. Valenti R Huber V Filipazzi P Pilla L Sovena G Villa A Corbelli A Fais S Parmiani G Rivoltini L Human Tumor-Released Microvesicles Promote the Differentiation of Myeloid Cells with Transforming Growth Factor-{beta}-Mediated Suppressive Activity on T Lymphocytes Cancer Res 2006, 66:9290-9298. 10.1158/0008-5472.CAN-06-1819 16982774
10. Colombo MP Piconese S Regulatory T-cell inhibition versus depletion: The right choice in cancer immunotherapy Nat Rev Cancer Nature Publishing Group 2007, 7:880-887. 10.1038/nrc2250 17957190
11. Martinelli M Bonezzi K Riccardi E Kuhn E Frapolli R Zucchetti M Ryan AJ Taraboletti G Giavazzi R Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. Br J Cancer 2007, 97:888-894. 17848949
12. Sacchi A Gasparri A Gallo-Stampino C Toma S Curnis F Corti A Synergistic Antitumor Activity of Cisplatin, Paclitaxel, and Gemcitabine with Tumor Vasculature-Targeted Tumor Necrosis Factor-{alpha} Clin Cancer Res 2006, 12:175-182. 10.1158/1078-0432.CCR-05-1147 16397040
13. Spinella F Rosano L Di Castro V Decandia S Nicotra MR Natali PG Bagnato A Endothelin-1 and Endothelin-3 Promote Invasive Behavior via Hypoxia-Inducible Factor-1{alpha} in Human Melanoma Cells Cancer Res 2007, 67:1725-1734. 10.1158/0008-5472.CAN-06-2606 17308114
14. Tagliabue E Agresti R Casalini P Mariani L Carcangiu ML Balsari A Veronesi U Menard S Linking survival of HER2-positive breast carcinoma patients with surgical invasiveness European Journal of Cancer 2006, 42:1057-1061. 10.1016/j.ejca.2005.12.021 16624551
15. Italian Sarcoma Group 2007 http://www.italiansarcomagroup.org
16. Italian Melanoma InterGroup 2007 http://www.melanomaimi.it
17. Italian Bone Marrow Transplant Group 2007 http://www.gitmo.net
18. Italian Trials in Medical Oncology 2007 http://www.itmo.it
19. Parmiani G Pilla L Castelli C Rivoltini L Vaccination of patients with solid tumours Ann Oncol 2003, 14:817-824. 10.1093/annonc/mdg246 12796017
20. Galeffi P Lombardi A Pietraforte I Novelli F Di Donato M Sperandei M Tornambe A Fraioli R Martayan A Natali P Benevolo M Mottolese M Ylera F Cantale C Giacomini P Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems Journal of Translational Medicine 2006, 4:39. 1592514 17010186 10.1186/1479-5876-4-39
21. Romagnani S Regulation of the T cell response. Clin Exp Allergy 2006, 36:1357-1366. 10.1111/j.1365-2222.2006.02606.x 17083345
22. Piovan E Tosello V Indraccolo S Masiero M Persano L Esposito G Zamarchi R Ponzoni M Chieco-Bianchi L la-Favera R Amadori A Differential Regulation of Hypoxia-Induced CXCR4 Triggering during B-Cell Development and Lymphomagenesis Cancer Res 2007, 67:8605-8614. 10.1158/ 0008-5472.CAN-06-4722 17875700
23. Velardi A Ruggeri L Alessandro Moretta Moretta L NK cells: A lesson from mismatched hematopoietic transplantation Trends in Immunology 2002, 23:438-444. 10.1016/S1471-4906(02)02284-6 12200065
24. Cavallo F Calogero RA Forni G Are oncoantigens suitable targets for anti-tumour therapy? Nat Rev Cancer 2007, 7:707-713. 10.1038/nrc2208 17700704
25. Booth CM Calvert AH Giaccone G Lobbezoo MW Eisenhauer EA Seymour LK Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). Eur J Cancer 2008, 44:25-29. 10.1016/j.ejca.2007.07.031 17845846
26. Bracci L Moschella F Sestili P La Sorsa V Valentini M Canini I Baccarini S Maccari S Ramoni C Belardelli F Proietti E Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor Infiltration Clin Cancer Res 2007, 13:644-653. 10.1158/1078-0432.CCR-06-1209 17255288
27. Camerini R Mackiewicz A Testori A Trefzer U Jassem J Ferraresi V Maio M Garbe C Lange A Carminati P on A large first-line, randomized, dose-finding, phase II study on thymosin-alpha 1 (T-alpha 1) plus dacarbazine (DTIC) with or without interferon-alpha (IFN-alpha) compared to DTIC plus IFN-alpha in stage IV melanoma. Tumor response and survival results ASCO Meeting Abstracts 2007, 25:8535.
28. Avogadri F Martinoli C Petrovska L Chiodoni C Transidico P Bronte V Longhi R Colombo MP Dougan G Rescigno M Cancer Immunotherapy Based on Killing of Salmonella-Infected Tumor Cells Cancer Res 2005, 65:3920-3927. 10.1158/0008-5472.CAN-04-3002 15867392
29. Ribas A Camacho LH Lopez-Berestein G Pavlov D Bulanhagui CA Millham R Comin-Anduix B Reuben JM Seja E Parker CA Sharma A Glaspy JA Gomez-Navarro J Antitumor Activity in Melanoma and Anti-Self Responses in a Phase I Trial With the Anti-Cytotoxic T Lymphocyte-Associated Antigen 4 Monoclonal Antibody CP-675,206 J Clin Oncol 2005, 23:8968-8977. 10.1200/JCO.2005.01.109 16204013
30. Attia P Phan GQ Maker AV Robinson MR Quezado MM Yang JC Sherry RM Topalian SL Kammula US Royal RE Restifo NP Haworth LR Levy C Mavroukakis SA Nichol G Yellin MJ Rosenberg SA Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti-Cytotoxic T-Lymphocyte Antigen-4 J Clin Oncol 2005, 23:6043-6053. 1473965 16087944 10.1200/JCO.2005.06.205
31. Sigalotti L Coral S Altomonte M Natali L Gaudino G Cacciotti P Libener R Colizzi F Vianale G Martini F Tognon M Jungbluth A Cebon J Maraskovsky E Mutti L Maio M Cancer testis antigens expression in mesothelioma: Role of DNA methylation and bioimmunotherapeutic implications. Br J Cancer 2002, 86:979-982. 10.1038/sj.bjc.6600174 11953832
32. Marrari A Iero M Pilla L Villa S Salvioni R Valdagni R Parmiani G Rivoltini L Vaccination therapy in prostate cancer. Cancer Immunol Immunother 2007, 56:429-445. 10.1007/s00262-006-0233-8 17031640
33. Queirolo P Acquati M Targeted therapies in melanoma Cancer Treatment Reviews 2006, 32:524-531. 10.1016/j.ctrv.2006.07.009 17008014
34. Pellegatta S Poliani PL Corno D Menghi F Ghielmetti F Suarez-Merino B Caldera V Nava S Ravanini M Facchetti F Bruzzone MG Finocchiaro G Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res 2006, 66:10247-10252. 10.1158/0008-5472.CAN-06-2048 17079441
35. Ridolfi R Petrini M Fiammenghi L Stefanelli M Ridolfi L Ballardini M Migliori G Riccobon A Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients. J Transl Med 2006, 4:36. 1562447 16914047 10.1186/ 1479-5876-4-36
36. Turin I Pedrazzoli P Tullio C Montini E La Grotteria MC Schiavo R Perotti C Locatelli F Carretto E Maccario R Siena S Montagna D GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia. Cytotherapy 2007, 9:499-507. 10.1080/14653240701405428 17786611
37. Mankoff S Brander C Ferrone S Marincola F Lost in Translation: Obstacles to Translational Medicine Journal of Translational Medicine 2004, 2:14. 420261 15149545 10.1186/1479-5876-2-14
38. Italian Network for Cancer Biotherapy 2007 http://www.nibit.org